Using MRI to assess hippocampal grading, physicians may be able to predict Alzheimer’s disease up to seven years before dementia.
MRI of the brain may detect Alzheimer’s disease up to seven years before signs appear, according to a study published in Human Brain Mapping.
Researchers from France, Canada, Denmark, and Spain undertook a prospective study to assess the efficiency of an MR-based hippocampal grading score that might detect incident dementia in patients who were cognitively intact. The subjects were followed for 12 years.
The study began with 538 subjects at baseline with Mini-Mental State Evaluation (MMSE) higher than 24 and analyzable MRI. At the end of the study, there were 309 subjects who did not have dementia.
The results showed that hippocampal grading for dementia predicted accuracy up to 72.5%, seven years before subjects began to show signs of Alzheimer’s disease while hippocampal volume was accurate up to 56.9%, and the Mini-Mental State Evaluation (MMSE) 56.9%. There was a gain of percentage points for hippocampal grade (73%) over hippocampal volume (64.6%).[[{"type":"media","view_mode":"media_crop","fid":"42998","attributes":{"alt":"MRI","class":"media-image media-image-right","id":"media_crop_4268438543649","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4680","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 120px; width: 160px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"©nav/Shutterstock.com","typeof":"foaf:Image"}}]]
“Compared with previous studies investigating new biomarkers for AD prediction over much shorter periods, the very long followup of the Three-City cohort demonstrates the important clinical potential of the proposed imaging biomarker,” the authors wrote. “The high accuracy obtained with this new imaging biomarker paves the way for computer-based prognostic aides to help the clinician identify cognitively intact subjects that are at high risk to develop AD,” they concluded.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
FDA Expands Clearance of MRI-Guided AI Platform for Deep Brain Stimulation and Lesioning Techniques
September 3rd 2024Utilizing a new machine learning model, the OptimMRI software may improve radiosurgery applications and lesioning techniques such as MRI-guided focused ultrasound through enhanced targeting of the inferolateral part of the ventral intermediate nucleus (VIM).
New Research Highlights Emerging MRI Contrast Agent for Bladder Imaging
August 21st 2024A new MRI contrast agent may provide a viable non-invasive alternative for the detection of interstitial cystitis, according to preliminary research presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan.